MOLECULAR CHARACTERISATION OF HEPATITIS B VIRUS VACCINE ESCAPE MUTANTS IN SOUTH AFRICA
|
|
- Silvester Casey
- 6 years ago
- Views:
Transcription
1 MOLECULAR CHARACTERISATION OF HEPATITIS B VIRUS VACCINE ESCAPE MUTANTS IN SOUTH AFRICA Penny Crowther Dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Master of Science in Medicine Johannesburg, 2005
2 DECLARATION I, Penny Crowther, declare that this dissertation is my own work. It is being submitted for the degree of Master of Science in Medicine at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University... day of ii
3 ABSTRACT Since the introduction of vaccination against hepatitis B virus (HBV) infection in South Africa, at least one case of infection despite vaccination has occurred. The purpose of this study was to determine whether this infection was the result of mutations within the region of the surface (S) gene encoding the a determinant epitopes of the hepatitis B surface antigen, which permitted viral vaccine-escape. HBV DNA was extracted from the serum and liver tissue of the patient and amplified within the complete bp genome and S gene, respectively. Following cloning, sequencing revealed a minor population displaying unique or uncommon S gene mutations that resulted in C138R, C139R, K141R, P142L, T143A, N146D, and T148A amino acid substitutions in the clones from the serum, and C139Y and D144N in the clones from the liver. Such isolates may represent South African HBV vaccine-escape mutants that caused chronic infection in the host prior to their reversion to wild-type. iii
4 ACKNOWLEDGEMENTS I would like to thank my supervisors, Dr Anna Kramvis and Professor Kew, for all their help and advice on this project, as well as for their endless support when it was needed most. To my parents, thank you for your encouragement and support during this degree, and for always being there for me. And to my friends in the Molecular Hepatology Research Unit, thank you for offering help and advice when it was needed, and for keeping me sane. I gratefully acknowledge the financial assistance provided to me by the University of the Witwatersrand, the National Research Foundation, and the Poliomyelitis Research Foundation. iv
5 TABLE OF CONTENTS DECLARATION... ii ABSTRACT... iii ACKNOWLEDGEMENTS... iv TABLE OF CONTENTS...v LIST OF FIGURES... viii LIST OF TABLES... ix ABBREVIATIONS...x Chapter 1: INTRODUCTION HEPATITIS B VIRUS History Natural History and Pathogenesis Epidemiology Classification Virion Structure Genomic Organisation and Gene Products Core Genes Polymerase Gene X Gene Surface Genes Replication Host Immune Responses Targeting HBV HBV Variants Genotypes Serological Subtypes HBV VACCINES Development Immune Response Implementation of Vaccination Vaccination Programme in South Africa SURFACE GENE MUTATIONS AND VACCINE ESCAPE RATIONALE AND AIMS OF THE STUDY...43 v
6 Chapter 2: MATERIALS AND METHODS SUBJECT AND SAMPLES DNA EXTRACTIONS DNA Extraction From Serum DNA Extraction From Liver Tissue AMPLIFICATION OF HBV DNA Full-Length Genome Amplification Surface Gene Amplification DETECTION OF AMPLIFIED DNA PRODUCTS CLONING OF AMPLIFIED DNA PRODUCTS Addition of 3 A Overhangs DNA Purification Cloning and Transformation Isolation of Recombinant Plasmid DNA GENOTYPING OF HBV DNA NUCLEOTIDE SEQUENCING OF HBV DNA SEQUENCING DATA AND PHYLOGENETIC ANALYSIS...66 Chapter 3: RESULTS DETECTION OF AMPLIFIED DNA PRODUCTS Full-Length Genome Amplicons Surface Gene Amplicons IDENTIFICATION OF HBV POSITIVE CLONES HBV GENOTYPING BY RFLP ANALYSIS Genotyping A to H Subgenotyping A1 versus A DNA SEQUENCING ANALYSIS Full-Length Genome Clones from Serum Surface Gene Clones from Serum Surface Gene Clones from Liver Tissue PHYLOGENETIC ANALYSIS...82 Chapter 4: DISCUSSION...84 Chapter 5: CONCLUSION...98 Chapter 6: REFERENCES...99 Appendix A: COMPLETE PATIENT INFORMATION vi
7 Appendix B: ETHICS APPROVAL AND PATIENT S INFORMED CONSENT.121 Appendix C: SOLUTIONS AND RECIPES vii
8 LIST OF FIGURES Figure 1.1 Schematic representation of the pathogenesis of hepatitis B virus infection in adults...5 Figure 1.2 World map showing geographic distribution of chronic HBV infection...8 Figure 1.3 Structure of HBV virions and subviral particles...12 Figure 1.4 Schematic representation of the HBV genome...14 Figure 1.5 Topological models of the three HBV surface proteins...21 Figure 1.6 HBV DNA synthesis by reverse transcription during replication...27 Figure 1.7 Diagrammatic representation of the major hydrophilic region of the HBsAg (aa ) occurring on the surface of the viral envelope...40 Figure 3.1 Detection of the amplified HBV full-length genome...67 Figure 3.2 Detection of the amplified HBV surface gene...68 Figure 3.3 Identification of full-length HBV positive clones...69 Figure 3.4 Identification of HBV surface gene positive clones...70 Figure 3.5 Restriction fragment length polymorphism (RFLP) analysis of the HBV surface gene (nt ) amplified from all of the serum and liver tissue clones...71 Figure 3.6 RFLP analysis of the HBV surface and polymerase gene (nt ) amplified from the serum full-length genome clones, showing the characteristic pattern of subgenotype A Figure 3.7 Chromatogram produced following automated sequencing of the core gene of the patient s HBV isolates...73 Figure 3.8 Amino acid sequence of part of the HBsAg (aa ), deduced from the nucleotide sequence of HBV S gene DNA (nt ) from the patient s serum- and liver-derived HBV clones...79 Figure 3.9 Schematic diagram of the HBsAg a determinant (aa ) showing single amino acid mutations found between aa 124 and Figure 3.10 Dendrogram obtained by neighbour-joining phylogenetic analysis of HBV complete genome sequences rooted on genotype F...83 viii
9 LIST OF TABLES Table 1.1 Relationship between HBV genotypes and subtypes, and corresponding characteristics...33 Table 1.2 Amino acid residues within HBsAg specifying the antigenic subtype determinants of HBV...34 Table 1.3 Common vaccine-escape mutations found between amino acids 124 and 147 within the a determinant of HBsAg...42 Table 2.1 Oligonucleotide primers used for the PCR amplification of the full-length HBV genome...49 Table 2.2 Oligonucleotide primers used for the PCR amplification of the surface gene of HBV...51 Table 2.3 Oligonucleotide primers used for the PCR amplification of parts of the S and P genes of HBV for A1 versus A2 genotyping...62 Table 2.4 Oligonucleotide primers used for sequencing the full-length genome and S gene of HBV...65 Table 3.1 Summary of mutations found within the region of the S gene encoding the MHR (aa ) of the HBsAg from HBV clones...81 Table A1 Patient information including ALT and AST levels, and HBV antigen and antibody status...98 ix
10 ABBREVIATIONS 3 A 3 deoxyadenosine aa ALT anti-hbc anti-hbe anti-hbs APC AST bp C cccdna ddntp DNA dntp DR dsdna EPI ER HBc HBcAg HBe HBeAg HBIg amino acid alanine aminotransferase hepatitis B core antibodies hepatitis B e antibodies hepatitis B surface antibodies antigen presenting cell aspartate aminotransferase base pair(s) core covalently closed circular deoxyribonucleic acid 2,3 -dideoxynucleoside triphosphate deoxyribonucleic acid deoxyribonucleotide triphosphate direct repeat double-stranded deoxyribonucleic acid Expanded Programme on Immunisation endoplasmic reticulum hepatitis B core hepatitis B core antigen hepatitis B e hepatitis B e antigen hepatitis B immunoglobulin x
11 HBs HBsAg HBV HBx HBxAg HCC kb kda LB MHC MHR mrna nt ORF P PCR pgrna PreC RFLP RNA RNase H rpm S V vol hepatitis B surface hepatitis B surface antigen hepatitis B virus hepatitis B x hepatitis B x antigen hepatocellular carcinoma kilobase(s) kilodalton(s) Luria-Bertani major histocompatibility complex major hydrophilic region messenger ribonucleic acid nucleotide(s) open reading frame polymerase polymerase chain reaction pregenomic ribonucleic acid precore restriction fragment length polymorphism ribonucleic acid ribonuclease H revolutions per minute surface volt(s) volume xi
12 Chapter 1: INTRODUCTION Hepatitis B, a serious liver disease induced by the hepatitis B virus (HBV), is a major global public health problem with the virus infecting over two billion people, of which approximately 387 million are chronically infected [World Health Organisation, 2002]. Since the development of hepatitis B vaccines, the number of newly acquired HBV infections has decreased substantially, to a very small fraction of the number acquired prior to vaccine administration. Nevertheless, vaccination does not protect all individuals from infection, because of either weak immune responses from the host or viral mutations, both of which allow vaccine escape of the virus. 1.1 HEPATITIS B VIRUS History Epidemic jaundice was first described by Hippocrates in the fifth century BC, when he was undoubtedly referring to individuals infected with hepatitis B virus and other agents capable of infecting the liver [Mahoney, 1999]. Epidemics of jaundice have continued to occur throughout history, particularly during wars in the 19 th and 20 th centuries [Mahoney, 1999]. The existence of a form of hepatitis that was parenterally transmitted by direct inoculation of blood or blood products was first documented by Lurman in Bremen, Germany, in 1883, 1
13 during a smallpox vaccination campaign that utilised contaminated human lymph [Lurman, 1885]. Early in the 20 th century, further outbreaks of parenterally acquired hepatitis occurred in various risk groups including patients who attended clinics for venereal diseases, diabetes, and tuberculosis; those who received blood transfusions; persons inoculated with mumps or measles serum; and military personnel who received yellow fever vaccines during World War II [Neefe et al., 1946; Mahoney, 1999]. Studies conducted during the 1930s and 1940s provided convincing evidence of a viral cause for hepatitis, with at least two etiologic agents [MacCallum and Bauer, 1944; Havens, 1946]. Subsequently, in 1947, MacCallum and Bauer (1947) proposed the nomenclature of hepatitis A for infectious hepatitis and hepatitis B for homologous serum hepatitis, terms which have since been adopted by the World Health Organisation (WHO) Committee on Viral Hepatitis. The distinctive seroepidemiologic features of hepatitis A and B were finally firmly established in a series of studies by Krugman and colleagues (1967) at the Willowbrook State School, New York, in the 1960s. The viral agent associated with hepatitis B was first isolated during serological studies conducted independently by Prince et al. (1964) and Blumberg et al. (1965). In searching for serum protein polymorphisms linked to diseases, Blumberg and colleagues identified an antigen termed Australia (Au) antigen in serum from patients with leukaemia, leprosy, and hepatitis, although the relationship of the antigen to hepatitis was not fully recognised until Prince (1968) subsequently established that the Au antigen occurred specifically in the serum of hepatitis B patients, and in 1973 the antigen was renamed the hepatitis B surface antigen (HBsAg) by the WHO. 2
14 In 1970, Dane and colleagues (1970) were the first to detect complete hepatitis B virions, or Dane particles. The 42 nm double-shelled spheres consisted of an outer envelope composed of HBsAg and an inner core containing hepatitis B core antigen (HBcAg) and endogenous DNA. A third antigen related to infectivity, designated hepatitis B e antigen (HBeAg), was subsequently described in 1972 by Magnius and Espmark (1972). In 1975, following these important breakthroughs in hepatitis research, hepatitis B vaccine studies were initiated using plasma-derived highly purified HBsAg particles, as it was found that antibodies targeting HBsAg were the neutralising antibodies for infectious HBV [Hollinger et al., 1974]. The safety and efficacy of these vaccines have since been established and continue to be maintained Natural History and Pathogenesis The hepatitis B virus is one of the most successful viral pathogens of humans because of the nature of its infections. Although the hepatocytes are the principal site of viral infection, pathological features of HBV infection have been identified in extrahepatic tissues such as the kidneys, lymph nodes, spleen, gonads, thyroid gland, adrenal glands, and bone marrow [Hollinger, 1996; Hilleman, 2003]. The liver plays an essential role in protein, carbohydrate, and lipid metabolism, energy storage and conversion, blood homeostasis, chemical detoxification, and immunity to microbial infections [Seeger and Mason, 2000]. Disruption of this organ by HBV infection therefore leads to a varying array of acute and chronic disease manifestations. 3
15 The consequences of acute HBV infection are highly variable, ranging from subclinical and asymptomatic to clinically apparent disease [Robinson, 1994]. The incubation period of hepatitis B the time from infection to the onset of signs or symptoms ranges from six weeks to six months, with the development of clinical symptoms being highly dependent on the age of the host [Mahoney, 1999]. Clinical manifestations do not generally occur in neonates, while infection produces typical illness in only 5 to 15% of children aged one to five years [McMahon et al., 1985; Mahoney, 1999]. In contrast, 33 to 50% of older children and adults develop symptomatic infections, varying in severity from mild to fulminant hepatitis with extensive liver necrosis (Figure 1.1) [Mahoney, 1999]. The clinical signs and symptoms of acute HBV infection that result from hepatic inflammation, include fever, jaundice, malaise, nausea, vomiting, abdominal pain, and increased serum levels of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [Francois et al., 2001]. Fulminant hepatitis, appearing suddenly, rapidly, and with great intensity, occurs in 1 to 2% of acute infections and has a case-fatality ratio of 63 to 93% [Mahoney, 1999]. The risk of developing chronic HBV infection defined as the presence of HBsAg in the serum for longer than six months decreases with age: approximately 90% of infected neonates, 50% of infants, 30% of children, and 10% of infected adults become HBV carriers [Hilleman, 2003]. Individuals with chronic hepatitis B infections generally have one of three types of disease chronic persistent hepatitis, chronic active hepatitis, or cirrhosis [Mahoney, 1999]. The degree of histological injury is often not reflected by the symptoms, such that persons with severe chronic liver disease may remain asymptomatic until late in the course of their illness [Mahoney, 1999]. Chronic active hepatitis leads to the development of liver fibrosis and often to cirrhosis, an irreversible condition in which 4
16 100% Transient Subclinical Infection 55% Resolution Resolution Inactive Cirrhosis Resolution Recovery Acute HBV Infection 35% 10% Chronic Infection 10-30% Chronic Hepatitis Cirrhosis Dysplasia HCC Death 99% Acute Hepatitis 1% 70-90% Asymptomatic Chronic Carrier 7-37% Fulminant Hepatitis 63-93% Death Figure 1.1 Schematic representation of the pathogenesis of hepatitis B virus infection in adults, indicating the percentage of infections that progress to various forms of the disease [Modified from Feitelson, 1994]. 5
17 regenerative nodules and fibrosis cause severe liver injury [Mahoney, 1999; Ganem and Prince, 2004]. Because of its stimulating effect on hepatocyte regeneration, cirrhosis may subsequently lead to the development of hepatocellular carcinoma (HCC), a malignant liver tumour that typically appears 25 to 30 years after the onset of infection [Mahoney, 1999] and culminates in the death of the individual (Figure 1.1). The pathogenesis of hepatitis B is extremely complex [Hilleman, 2003]. Although HBV causes hepatitis B, the virus itself is not directly cytopathic in humans and therefore causes only limited damage to the liver [Francois et al., 2001]. The clinical effects of the disease are, instead, the result of the destruction of infected hepatocytes by the host immune defence system [Hollinger, 1996]. Variations in the clinical outcome of HBV infection are therefore caused by differences in the host response and, possibly, by mutations in the HBV genome that result in the production of variant viruses [Feitelson, 1994; Kidd- Ljunggren, 1996]. Although the mechanism of liver injury in acute and chronic hepatitis B is not completely defined [Robinson, 1994], it is known that aggressive immune responses, involving both major histocompatibility complex (MHC) class II-restricted, CD4+ helper cells and MHC class I-restricted, CD8+ cytotoxic T-lymphocytes [Ganem and Prince, 2004], result in symptomatic acute hepatitis and viral clearance, while non-aggressive host responses that reflect weak T-cell-mediated immune responses lead to an asymptomatic chronic viral carrier state [Hilleman, 2003]. Of the approximately 387 million chronic carriers of HBV worldwide, 15-40% eventually develop cirrhosis, liver failure, or HCC [Lok, 2002]. In addition, HBV infection results in 6
18 to 1.2 million deaths each year, making it the tenth leading cause of death worldwide, while HCC is the fifth most common cancer, killing to people per year [Lavanchy, 2004] Epidemiology Present mainly in blood, saliva, and semen, hepatitis B virus is transmitted horizontally by percutaneous or permucosal exposure to infectious blood and body fluids, or perinatally from an infected mother to her infant during the perinatal period [Mahoney, 1999; Alter, 2003]. As a highly resilient virus, HBV is resistant to breakdown and can therefore also survive outside the body for longer than a week [Alter, 2003; Lavanchy, 2004]. The prevalence of HBV infection and patterns of transmission vary greatly in different geographic regions of the world and in different population subgroups (Figure 1.2) [Mahoney, 1999; Lavanchy, 2004]. Approximately 45% of the global population live in areas where the prevalence of chronic HBV infection is high (8% or more of the population is HBsAg positive), 43% live in areas with moderate prevalence (2 to 7% of the population is HBsAg positive), and 12% live in areas of low endemicity (less than 2% of the population is HBsAg positive) [Mahoney, 1999]. 7
19 Figure 1.2 World map showing geographic distribution of chronic HBV infection [Strauss and Strauss, 2002]. In areas of high endemicity including sub-saharan Africa, most of Asia and the Middle East, the Amazon Basin of South America, the Pacific Islands, and other special population groups such as Native Alaskans, Australian Aborigines, and Maoris in New Zealand the most common source of infection is through perinatal transmission or through infection acquired horizontally during early childhood [Mahoney, 1999; de Franchis et al., 2003]. The high proportion of infectious HBV carriers explains the high rate of perinatal and childhood transmission, which perpetuate the high prevalence of HBV infections in these endemic countries [de Franchis et al., 2003]. Thus, the lifetime risk of HBV infection in such highly endemic areas is greater than 60% [Mahoney, 1999]. In areas of moderate endemicity, such as North Africa, some of the Middle East, the southern parts of Eastern and Central Europe, the USSR, the Indian subcontinent, and part of Brazil, the current important modes of HBV transmission are needle sharing among 8
20 injecting drug users, nosocomial (hospital) transmission, tattooing, and body piercing [de Franchis et al., 2003]. In contrast to highly endemic countries, the lifetime risk of HBV infection in intermediate areas is 20 to 60% [Mahoney, 1999], with over 95% of new infections being acquired during adulthood [de Franchis et al., 2003]. Areas of low HBV endemicity include Northwest Europe, Australia, and North America [Mahoney, 1999; de Franchis et al., 2003]. In these regions, most HBV infections are acquired by horizontal transmission in early adulthood: through needle sharing among injecting drug users and through sexual contacts [de Franchis et al., 2003; Lavanchy, 2004]. Other rare sources of infection include contaminated surgical instruments, needlestick injuries by hospital personnel, and blood transfusions [Alter, 2003]. The lifetime risk of infection in these developed countries is less than 20%, with most infections occurring amongst well-defined risk groups [Mahoney, 1999]. In South Africa, a country with intermediate HBV endemicity and pockets of high endemicity [Dusheiko et al., 1989a; Dusheiko et al., 1989b], more than 70% of the population has been exposed to HBV and approximately four million (almost entirely black people) are carriers [Kew, 1996; Tsebe et al., 2001]. Of these, an estimated to people die per annum [Mphahlele et al., 2002]. The majority of black carriers of HBV are infected in early childhood by horizontal transmission, probably by infected blood or saliva through skin abrasions, lesions, and bites, and tribal scarification or tattooing with unsterilised sharp instruments [Kew, 1996; Kiire, 1996]. Their main sources of infection are other family members, such as highly infectious siblings aged between one and five years, and playmates of the same age [Kew, 1996]. In contrast to it being the major source of HBV infection in Southeast Asia, maternal-infant perinatal infection is 9
21 relatively uncommon in black Africans [Kew, 1996]. The carrier rate of HBV differs regionally in South Africa, with higher rates of infection in rural areas (5 to 15%) than in urban areas (less than 5%) [Dusheiko et al., 1989a; Dusheiko et al., 1989b]; however, this difference cannot be explained by socioeconomic inequalities [Mphahlele et al., 2002] Classification The hepatitis B virus (HBV) was the first member to be discovered within the family of viruses designated the Hepadnaviridae (hepatotropic DNA viruses) [van Regenmortel et al., 2000]. This family was subsequently divided into two groups, the orthohepadnaviruses (mammalian hepadnaviruses), of which HBV is the prototype member, and the avihepadnaviruses (avian hepadnaviruses) [van Regenmortel et al., 2000]. Hepadnaviruses share many epidemiologic and biological features. As their names imply, all hepadnaviruses are hepatotropic and can cause hepatitis in their native host, and all exhibit a narrow host range that may be determined by the identity of the host hepatocyte receptor [Strauss and Strauss, 2002]. However, in contrast to orthohepadnaviruses, which mostly exhibit horizontal transmission, avihepadnaviruses are transmitted vertically [Strauss and Strauss, 2002]. 10
22 1.1.5 Virion Structure Each infectious HBV virion, or Dane particle, measuring 42 nm in diameter, consists of a spherical outer envelope that is 7 nm thick and encloses a nm electron-dense, icosahedral core particle containing the viral nucleic acid and DNA polymerase (Figure 1.3) [Hollinger, 1996]. The envelope is composed of host-derived lipids, in which three types of different sized viral surface glycoproteins are embedded [Seeger, 1994]. In the blood of HBV-infected patients, titres of Dane particles can range from less than 10 4 /ml to greater than 10 9 /ml [Ganem, 1996]. In addition to complete Dane particles, sera of HBV infected individuals also contain two distinct subviral particles: spherical 20 nm particles and tubular or filamentous particles of 20 nm diameter and variable length (Figure 1.3) [Hollinger, 1996]. Both such particles are composed exclusively of viral surface glycoproteins (~70%) and host-derived lipids, such as phospholipids, cholesterol, and triglycerides [Ganem, 1996]. However, unlike Dane particles, subviral particles lack nucleic acid and are thus non-infectious, although they remain highly immunogenic [Ganem, 1996]. The most abundant of the three types of HBV particles, 20 nm spheres can reach titres as high as /ml, while filaments can reach titres of /ml [Ganem, 1996; Locarnini, et al., 2003]. As such, subviral particles comprise over 90% of the total HBV particles in the sera of infected individuals [Paran et al., 2003]. This excess of viral surface antigen particles is thought to adsorb neutralising antibodies, thereby helping to shield the infectious virions from host defences [Ganem, 1996]. 11
HBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationVirion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics
Hepadnaviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Hepatitis viruses A group of unrelated pathogens termed hepatitis viruses cause the vast majority
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationRama Nada. - Malik
- 2 - Rama Nada - - Malik 1 P a g e We talked about HAV in the previous lecture, now we ll continue the remaining types.. Hepatitis E It s similar to virus that infect swine, so its most likely infect
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationViral hepatitis. The word hepatitis means inflammation of the liver. There are five main types of viral hepatitis: A, B, C, D, E
Viral hepatitis The word hepatitis means inflammation of the liver There are five main types of viral hepatitis: A, B, C, D, E Hepatitis A and E are typically caused by ingestion of contaminated food or
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationHepatitis B (Part 1 - intro)
Hepatitis B (Part 1 - intro) The Hepatitis B virus (HBV) l Virology Discovered in 1966 double-stranded DNA virus l family of hepadnaviruses l HBV unique to Humans (Primates too in laboratory studies) no
More informationProperties of HBV. HBV : Structure. Hepatitis B Virus. Partial dsdna and Enveloped : within the envelope we have (HBsAg) on the surface.
Hepatitis B Virus Partial dsdna and Enveloped : within the envelope we have (HBsAg) on the surface. Also we have Nucleic Acid inside (which is partial ds DNA) and the Nucleocapcid protein which is the
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationHepatitis A-E Viruses. Dr Nemes Zsuzsanna
Hepatitis A-E Viruses Dr Nemes Zsuzsanna Viral Hepatitis - Historical Perspectives Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D C Parenterally transmitted HGV, TTV, SEN, other
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationCDC website:
Hepatitis B virus CDC website: http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_b/slide_1.htm Relevance Key Features es of Hepatitis t B Virus 250 million people infected worldwide. In areas of
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationHAV HBV HCV HDV HEV HGV
Viral Hepatitis HAV HBV HCV HDV HEV HGV Additional well-characterized viruses that can cause sporadic hepatitis, such as yellow fever virus, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, rubella
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationLifetime risk of infection >60% Early childhood infections common
Hepatitis Community Medicine HBV Public health sig HBV is 100 times more infectious than HIV. >350 million chronically infected worldwide. >1 million people die annually of HBV- related chronic liver disease.
More informationUpdate on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection
CLINICAL MICROBIOLOGY REVIEWS, Apr. 1999, p. 351 366 Vol. 12, No. 2 0893-8512/99/$04.00 0 Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection FRANCIS J. MAHONEY* Office of the
More informationViral Hepatitis - Historical Perspective
Viral Hepatitis - Historical Perspective Infectious A E Enterically transmitted Viral hepatitis NANB Serum B D F, G,? other C Parenterally transmitted Before the discovery of hepatitis A virus (HAV) and
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationHepatitis B Virus hepadnaviruses genome is a small, circular, partly double-stranded DNA
Hepatitis B Virus HBV is the major member of the hepadnaviruses. Other members of this family (Box 65-3) include woodchuck, ground squirrel, and duck hepatitis viruses. These viruses have limited tissue
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationHepatitis B. Data from the Travel Health Surveillance Section of the Health Protection Agency Communicable Disease Surveillance Centre
Hepatitis B Introduction Hepatitis B virus is one of the most prevalent viruses worldwide and is a major cause of chronic liver disease and hepatocellular carcinoma. It is a hepadnavirus, consisting of
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationViral Hepatitis. Author: Nicolene Naidu
Viral Hepatitis Author: Nicolene Naidu Bachelor of Biological Science (Cellular Biology), Bachelor of Medical Science (Medical Microbiology) (Honours) The liver is the largest gland in the human body and
More informationHepatitis B. Pathology Research Report By: Hannah Matthews Spring Abstract
Hepatitis B Pathology Research Report By: Hannah Matthews Spring 2016 Abstract The hepatitis B virus (HBV) is an infectious virus that causes inflammation and infection of the liver. This injury to the
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationHepatitis Serology and Background Notes
Hepatitis Serology and Background Notes Updated and presented by David Dickeson 2012 Collated by Evelyn Crewe 2010 Centre for Infectious Diseases & Microbiology Laboratory Services Institute of Clinical
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationViral Hepatitis. Viral Hepatitis. Infectious Disease Epidemiology BMTRY 713 Viral Hepatitis. March 23, Selassie AW (DPHS, MUSC) 1
Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 19 Learning Objectives 1. Describe the epidemiology of viral hepatitis 2. Identify the biologic characteristics of the various viruses
More informationViral Hepatitis. Background
Viral Hepatitis Background Hepatitis or inflammation of the liver can be caused by infectious and noninfectious problems. Infectious etiologies include viruses, bacteria, fungi and parasites. Noninfectious
More informationViral Hepatitis in Children DR. HOSSAIN IBRAHIM AGEEL PEDIATRIC GASTROENTEROLOGIST PEDIATRIC DEPARTMENT KFCH JAZAN
Viral Hepatitis in Children DR. HOSSAIN IBRAHIM AGEEL PEDIATRIC GASTROENTEROLOGIST PEDIATRIC DEPARTMENT KFCH JAZAN General Concepts Hepatitis = 'inflammation of the liver'. Virus causes: Hepatotropic and
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHEPATITIS VIRUSES ACUTE HEPATITIS: HEPATITIS A HEPATITIS B HEPATITIS C HEPATITIS D HEPATITIS E HEPATITIS G
HEPATITIS VIRUSES ACUTE HEPATITIS: HEPATITIS A HEPATITIS B HEPATITIS C HEPATITIS D HEPATITIS E HEPATITIS G Viral Hepatitis - Historical Perspectives Infectious A E Enterically transmitted Viral hepatitis
More informationA VIEW OF DEMOGRAPHIC FACTORS OF HEPATITIS B VIRUS INFECTION IN DURRES REGION DURING
Interdisplinary Journal of Research and Development Alexander Moisiu University, Durrës, Albania Vol (IV), No.2, 2017 Paper presented in 1 -st International Scientific Conference on Professional Sciences,
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationWe need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles
0 We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles in diagnosing patients but also after diagnosis, helping
More informationThis is a free sample of content from The Hepatitis B and Delta Viruses. Click here for more information on how to buy the book.
Index A Acute liver failure (ALF), viral hepatitis, 7 Adalimab, hepatitis B management in immunosuppression patients, 279 Alemtuzumab, hepatitis B management in immunosuppression patients, 280 ALF. See
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationAlla ricerca del virus nascosto (quando il virus dell epatitie B si occulta )
Alla ricerca del virus nascosto (quando il virus dell epatitie B si occulta ) Giovanni Raimondo Epatologia Clinica e Biomolecolare Policlinico Universitario di Messina UI/ml pg/ml HBsAg HBeAg + anti-hbe
More informationNotes Setting the Scene
We need to know who is at risk of Hepatitis B and C infections so that we can identify them and offer them testing. Primary care has important roles in diagnosing patients but also after diagnosis, helping
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationReview HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B
Antiviral Therapy 2011; 16:1169 1186 (doi: 10.3851/IMP1982) Review HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B Beom Kyung Kim 1, Peter A Revill 2, Sang
More informationEPIDEMIOLOGICAL HETEROGENEITY OF INFECTIONS WITH HEPATITIS B AND D VIRUSES IN BRAZIL
PREVENTION AND CONTROL OF VIRAL HEPATITIS IN BRASILAND OTHER LATIN AMERICAN COUNTRIES BRASÍLIA, BRAZIL 21 DE MARCH 2014 EPIDEMIOLOGICAL HETEROGENEITY OF INFECTIONS WITH HEPATITIS B AND D VIRUSES IN BRAZIL
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationHEPATITIS B: are escape mutants of concern?
VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationkeyword: hepatitis Hepatitis
www.bpac.org.nz keyword: hepatitis Hepatitis Key reviewers: Dr Susan Taylor, Microbiologist, Diagnostic Medlab, Auckland Dr Tim Blackmore, Infectious Diseases Physician and Microbiologist, Wellington Hospital,
More informationGENOTYPING AND MOLECULAR CHARACTERIZATION OF HEPATITIS B VIRUS (HBV) FROM HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED INDIVIDUALS IN SOUTHERN AFRICA
GENOTYPING AND MOLECULAR CHARACTERIZATION OF HEPATITIS B VIRUS (HBV) FROM HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED INDIVIDUALS IN SOUTHERN AFRICA Euphodia Makondo Dissertation submitted to the Faculty
More informationHepatitis C in Australia:
Hepatitis C in Australia: Epidemiology and Clinical Presentation (and a bit of virology ) A/Prof Mark Douglas Hepatitis C - Distribution Te and Jensen 2010 Clin Liver Dis Hepatitis C Epidemiology Estimated
More informationHepatitis B. Hepatitis Viruses. Hepatitis Viruses. Hepatitis Viruses
Hepatitis Viruses Hepatitis B History and Overview of Hepatitis B Testing in Australia Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Cytomegalovirus Epstein-Barr Virus Hepatitis Viruses Hepatitis
More informationCommunity Dialogue Series The Lao Cultural Center. Hepatitis B in Asian Communities
Community Dialogue Series The Lao Cultural Center Hepatitis B in Asian Communities Jian-Min Yuan, MD, PhD Associate Professor Division of Epidemiology and Community Health School of Public Health & The
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationLiver Disease. By: Michael Martins
Liver Disease By: Michael Martins Recently I have been getting a flurry of patients that have some serious liver complications. This week s literature review will be the dental management of the patients
More informationHow does HBV affect the liver?
Hepatitis B Why is the liver important? Your liver is a vital organ that performs many essential functions. It s the largest solid organ in the body and is located under your rib cage on the upper right
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To provide guidelines on the treatment and care of patients with Hepatitis. POLICY Hepatitis is an injury to hepatic cells and an inflammatory process in the liver. The major causes
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationPUBLICATION REPORT 06/99 UPDATE ON DIAGNOSIS, MANAGEMENT, AND PREVENTION OF HEPATITIS B VIRUS INFECTION. Francis J. Mahoney
PUBLICATION REPORT 1906 06/99 UPDATE ON DIAGNOSIS, MANAGEMENT, AND PREVENTION OF HEPATITIS B VIRUS INFECTION By Francis J. Mahoney U.S. NAVAL MEDICAL RESEARCH UNIT NO. 3 (CAIRO, ARAB REPUBLIC OF EGYPT)
More informationGastroenteritis and viral infections
Gastroenteritis and viral infections A Large number of viruses are found in the human gut; these include some that are associated with gastroenteritis Rotaviruses Adenoviruses 40/41 Caliciviruses Norwalk-like
More informationHIV AND HEPATITIS B/C CO-INFECTION IN KWAZULU-NATAL FROM 2002 TO 2010: A RETROSPECTIVE DATABASE ANALYSIS
HIV AND HEPATITIS B/C CO-INFECTION IN KWAZULU-NATAL FROM 2002 TO 2010: A RETROSPECTIVE DATABASE ANALYSIS Submitted to: SCHOOL OF NURSING AND PUBLIC HEALTH UNIVERSITY OF KWAZULU-NATAL DURBAN SOUTH AFRICA
More informationhepatitis B virus Done by: Afnan Alsaqqaf Juveria Fatima Maryam Essa Medical virology (450) KING SAUD UNIVERSITY
Medical virology (450) KING SAUD UNIVERSITY hepatitis B virus Done by: Afnan Alsaqqaf Juveria Fatima Maryam Essa Hepatitis B Introduction Hepatitis B is an infectious disease caused by the hepatitis B
More informationHBV PUBLIC HEALTH IMPLICATIONS
جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationAPPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College
APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHepadnaviruses: Variations on the Retrovirus Theme
WBV21 6/27/03 11:34 PM Page 377 Hepadnaviruses: Variations on the Retrovirus Theme 21 CHAPTER The virion and the viral genome The viral replication cycle The pathogenesis of hepatitis B virus A plant hepadnavirus
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationHepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003
Hepatitis 2003 STARS Program Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003 Outline n Hepatitis A Epidemiology and screening Transmission n Hepatitis B Epidemiology
More informationViruse associated gastrointestinal infection
Viruse associated gastrointestinal infection Dr. Hala Al Daghistani Rotaviruses Rotaviruses are a major cause of diarrheal illness in human (infants), and young animals, including calves and piglets. Infections
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationJMSCR Volume 03 Issue 01 Page January 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Seroprevalence of HBV among HIV Patients and Blood Donors Author Dr. Vedavati B I 1, Dr. Amrutha Kumari B 2, Dr. Venkatesha D 3 Mysore
More informationHuman Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
More information2/7/2013. The ABC s (and D & E s) of the Viral Hepatitides Part 1 INTRODUCTION
The ABC s (and D & E s) of the Viral Hepatitides Part 1 Thomas Novicki PhD DABMM Clinical Microbiologist Division of Laboratory Medicine novicki.thomas@marshfieldclinic.org Objectives 2 1. Explain the
More informationHepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review
Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission
More informationFINANCIAL DISCLOSURE
FINANCIAL DISCLOSURE People who work at NIH only dream about having financial disclosures Wait, this just in. The US government has now banned dreaming CRITICAL NON-FINANCIAL DISCLOSURES Nothing I say
More informationSome living things are made of ONE cell, and are called. Other organisms are composed of many cells, and are called. (SEE PAGE 6)
Section: 1.1 Question of the Day: Name: Review of Old Information: N/A New Information: We tend to only think of animals as living. However, there is a great diversity of organisms that we consider living
More informationVIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS?
VIRAL AND AUTOIMMUNE HEPATITIS Arthur M. Magun, M.D. Clinical Professor of Medicine WHAT IS HEPATITIS? Inflammation of the liver Almost always, inflammation implies elevation in liver enzymes AST and ALT
More informationCANSA DETECTIVES. The very real prospect of eradicating liver cancer in southern Africa
CANSA DETECTIVES The very real prospect of eradicating liver cancer in southern Africa CANSA Head Office PO Box 2121 Bedfordview 2008 Tel: 27 11 616 7662 Fax: 27 11 622 3424 e-mail: research@cansa.org.za
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationHBV in New Zealand Community HBV screening to long-term follow-up
HBsAg+ icteric hepatitis (n) % anti-hbcore+ 26/9/214 HBV in New Zealand Community HBV screening to long-term follow-up John Hornell, CEO, A registered charitable trust whose mission is: To improve health
More information